Mitochondrial Ferroptosis Inhibitor
Neurodegenerative Disorders (e.g., Alzheimer's, Parkinson's)
PreclinicalActive
Key Facts
Indication
Neurodegenerative Disorders (e.g., Alzheimer's, Parkinson's)
Phase
Preclinical
Status
Active
Company
About Mitotech
Mitotech is a clinical-stage biotech developing first-in-class, mitochondria-targeted therapeutics for diseases driven by mitochondrial dysfunction. Its lead platform centers on small molecules designed to accumulate in mitochondria, combat oxidative stress, inhibit ferroptosis, and enhance cellular energy expenditure. The company has active preclinical and clinical programs targeting large markets such as obesity/MASH and neurodegenerative disorders, positioning itself at the forefront of mitochondrial medicine.
View full company profile